Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02545049 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 7,352
- Enrollment target
NCT02545049: Completed Phase 3 study, sponsored by Bayer.
NCT02545049 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 7,352 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (852% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02545049, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7,352 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placebo.
Primary Outcome
Number of participants with the first occurrence of the primary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were reported as descriptive result.
Interventions
- DRUG Placebo
- DRUG Finerenone (BAY94-8862)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,352 participants |
| Start Date | 2015-09-17 |
| Est. Completion | 2021-02-02 |
| Phase | Phase 3 |
What the finished NCT02545049 record still lists
NCT02545049 is an interventional study that assigns participants to a tested intervention. Its 7,352 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (852% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02545049 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02545049 about?
NCT02545049 is a clinical study titled "Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease". The purpose of this study was to evaluate whether oral finerenone (study drug), in addition to standard daily therapy, is effective and safe in treating patients with type 2 diabetes mellitus and diabetic kidney disease, when compared to a placebo.
What is the current status of trial NCT02545049?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7,352 participants. The study started on 2015-09-17. Estimated completion is 2021-02-02.
What interventions are being tested in trial NCT02545049?
The interventions under investigation include: Placebo (DRUG), Finerenone (BAY94-8862) (DRUG).
Who is sponsoring clinical trial NCT02545049?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02545049's enrollment target sits among peer trials
7,352 34th of 2000 higher than 1,967 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02915198 · 7,410 participants · Phase 4
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
- NCT00439049 · 7,500 participants
Substance Abuse Pre-Treatment Screening Study
- NCT04809740 · 7,500 participants · NA
Evaluating the Implementation and Impact of Navigator-delivered ePRO System
- NCT05199701 · 7,500 participants · NA
Prospective Case Collection Study for New Mammography Technologies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI